Skip to main content
. 2015 Jul 15;8(7):11174–11180.

Table 1.

Baseline Clinical Characteristics of control and type 2 diabetic patients stratified by albuminuria status

Control Normo Microal Macroal p-value
Number 49 72 85 51
Age (years) 62.16±8.84 60.47±11.44 61.79±11.84 62.07±11.08 0.223
Gender (male/female) 28/21 30/42 41/44 28/23 0.316
BMI (kg/m2) 23.33±3.85 23.68±3.92 23.18±3.97 22.57±3.78§ 0.482
Duration of diabetes (years) - 6.33±3.31 9.61±4.81§ 10.96±2.93§ <0.001
SBP (mmHg) 117.65±9.25 121.69±15.72 124.83±11.14 129.37±12.60 0.073
DBP (mmHg) 74.46±9.34 78.25±10.29 77.59±8.04 80.56±9.37 0.021
HbA1c (%) 4.94±0.97 7.13±1.51 8.22±1.76 7.95±1.76 <0.001
TCHOL 202.01±20.64 188.55±45.76 192.64±33.17 203.58±51.47 0.117
Triglyceride (mg/dL)* 126.6 (91.6-153.9) 141.3 (93.4-179.5) 136.7 (110.7-163.4) 142.0 (104.1-176.8) 0.268
LDL (mg/dL) 116.00±26.01 111.67±39.04 110.61±28.98 113.67±35.56 0.591
HDL (mg/dL) 60.66±20.38 48.21±16.51 51.66±15.34 52.20±18.38 0.001
eGFR (ml/min/1.73 m2) 96.05±10.10 91.35±15.1 88.48±16.71, 74.28±16.21,,, <0.001
u-ACR (ng/mg)* 13.3 (7.2-16.3) 12.9 (8.9-17.1) 94.5 (55.8-132.3), 829.1 (596.4-1076.8),,# <0.001
Homocysteine (μmol/L)* 8.98±1.74 8.50±1.81 10.23±1.97, 14.45±2.37,,# <0.001
Hypoglycemic agents, (%) - 21 (29.2) 47 (55.3) 27 (53.0) <0.001
Antihypertensive agents, (%) - 16 (22.2) 56 (55.9) 32 (62.7) <0.001

Note: Data are reported as mean ± SD for normally distributed values or median (interquartile range) for non-normally distributed values. P-value indicates the significance of differences between group means as determined by ANOVA.

*

Logarithm-transformed values were used;

P<0.05 vs. control;

P<0.001 vs. control;

§

P<0.05 vs. normo;

P<0.001 vs. normo;

P<0.05 vs. micro;

#

P<0.001 vs. micro.

Abbreviation: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; TCHOL, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; u-ACR, Urine Albumin/urine Creatinine.